AbCellera Biologics Inc. AbCellera Biologics Inc.

AbCellera Biologics Inc.

ABCL

주식 순위 #4176
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
주가
$11.85
마지막 동기화: 2026-10-16
시가총액
$3.84B
변동 (1일)
-6.59%
변동 (1년)
111.90%
국가
CA
거래 AbCellera Biologics Inc. (ABCL)

카테고리

Healthcare
AbCellera Biologics Inc. (ABCL)의 EPS
June 2026 기준 EPS TTM: $-0.54
AbCellera Biologics Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-0.54입니다. 2023년 말에는 회사의 EPS가 $-0.51였으며, 이는 2022년의 EPS $0.56와 감소입니다.
AbCellera Biologics Inc.의 EPS 기록 (2018 ~ 2026)
매년 말의 EPS
연도 EPS 변화
2026 (TTM) $-0.54 -1.82%
2024 $-0.55 7.84%
2023 $-0.51 -191.07%
2022 $0.56 0.00%
2021 $0.56 75.00%
2020 $0.32 -3,206.80%
2019 $-0.01 -615.00%
2018 0.00 0.00%
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -3,307.41%
US
$-7.98 1,377.78%
US
$-5.29 879.63%
AU
- -
CH
$27.74 -5,237.04%
NL